You are here

SCORPION Natural Formula 41,000 MG capsules

Safety advisory

27 October 2020

SCORPION Natural Formula 41,000 MG capsules pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested a product labelled SCORPION Natural Formula 41,000 MG and found that:

  • the capsules contain the undeclared substances dapoxetine and tadalafil.

Consumers are advised that dapoxetine and tadalafil are prescription-only (S4) medicines in Australia.

The supply of SCORPION Natural Formula 41,000 MG capsules containing undisclosed dapoxetine and tadalafil is illegal.

SCORPION Natural Formula 41,000 MG capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

Information for consumers

  • Stop taking SCORPION Natural Formula 41,000 MG capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of SCORPION Natural Formula 41,000 MG capsules from entering Australia.

If these capsules are found at the border by the ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas internet sites and has produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653

Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products